Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2022

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment

Annabelle Walz
  • Fonction : Auteur
Christin Gumpp
  • Fonction : Auteur
Mohammed Cherkaoui-Rbati
  • Fonction : Auteur
Nathalie Gobeau
  • Fonction : Auteur
Jeremy Gower
  • Fonction : Auteur
Miles Davenport
  • Fonction : Auteur
Matthias Rottmann
  • Fonction : Auteur
James Mccarthy
Jörg Möhrle
Maria Rebelo
  • Fonction : Auteur
Claudia Demarta-Gatsi
  • Fonction : Auteur
David Khoury

Résumé

The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumeration of parasites may result in underestimation of drug activity for some compounds, potentially confounding its use as a metric for assessing antimalarial activity in vivo . Here, we report a study of the effect of artesunate on Plasmodium falciparum viability in humans and in mice.

Dates et versions

hal-04287445 , version 1 (15-11-2023)

Identifiants

Citer

Georges Radohery, Annabelle Walz, Christin Gumpp, Mohammed Cherkaoui-Rbati, Nathalie Gobeau, et al.. Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment. Antimicrobial Agents and Chemotherapy, 2022, 66 (7), ⟨10.1128/aac.00114-22⟩. ⟨hal-04287445⟩

Collections

32 Consultations
0 Téléchargements

Altmetric

Partager

  • More